Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic Patients

NCT02390206 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 239

Last updated 2017-10-02

No results posted yet for this study

Summary

The purpose of this study is to document the effectiveness of treating chronic post-stroke spastic patients with Botulinum Toxin type A.

Conditions

  • Spasticity

Sponsors & Collaborators

Principal Investigators

  • Ipsen Study Director · Ipsen

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-08-28
Completion
2017-08-28

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02390206 on ClinicalTrials.gov